Investigating biomarkers of Staphylococcus aureus bacteremia in patients - School of Pharmacy
Por um escritor misterioso
Descrição
The Centers for Disease Control identifies methicillin-resistant S. aureus (MRSA) as a serious health threat with greater than 100,000 invasive infections and 20,000 patient deaths annually in the United States. Despite recent advancements in available treatment options for methicillin-sensitive S.
Defining persistent Staphylococcus aureus bacteraemia: secondary analysis of a prospective cohort study - The Lancet Infectious Diseases
Biofilm and virulence production during antimicrobial exposures - School of Pharmacy
Current Paradigms of Combination Therapy in Methicillin-Resistant Staphylococcus aureus (MRSA) Bacteremia: Does it Work, Which Combination, and For Which Patients? - Abstract - Europe PMC
Timing of follow-up blood cultures for community-onset bacteremia
Methicillin-resistant Staphylococcus aureus: novel treatment approach breakthroughs, Bulletin of the National Research Centre
Detailed Molecular Signature Accurately Predicts Death from S. aureus Bacteremia
Investigational agents for the treatment of methicillin-resistant Staphylococcus aureus (MRSA) bacteremia: progress in clinical trials: Expert Opinion on Investigational Drugs: Vol 31, No 3
Mechanism and pharmacodynamics of glyco/lipopeptide synergy with older antimicrobials - School of Pharmacy
Risk Factors for Nephrotoxicity in Methicillin-Resistant Staphylococcus aureus Bacteraemia: A Post Hoc Analysis of the CAMERA2 Trial
Patients included in the safety and efficacy analysis
de
por adulto (o preço varia de acordo com o tamanho do grupo)
